XORTX Therapeutics Inc. (“XORTX” or the “Company”) a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, has announced the filing of a provisional patent based upon recent discoveries specific to polycystic kidney disease. The provisional patent is entitled “Compositions and Methods for Diagnosis, Treatment of and Prevention of Kidney Disease”. The provisional patent is based upon new evidence related to a previously unknown mechanism of injury associated with:
- aberrant purine metabolism in kidneys during the progression of polycystic kidney disease;
- the health consequences of increased xanthine oxidase expression in polycystic kidney disease; and
- the health consequences of high uric acid concentration on both structure and function of polycystic kidneys.
Based on the Thelansis market insight report on Autosomal dominant polycystic kidney disease (ADPKD), which provides a clear understanding of disease area background, epidemiology, current and future competitions, the country-specific standard of care, and the complete market forecast for 2020 to 2030.
The annual prevalence of ADPKD varies between 335 to 450 cases per million population in the USA. Hypertension is a common and serious complication of ADPKD, often occurring in 50% – 70% of ADPKD patients early in the disease, before the appearance of renal dysfunction.
Comprehensive insight on patient segmentation based on Age, Sex, stages (Stage – 0, I, II, III, IV, V), Disease Manifestation & Mutation (PKD1 and PKD2) has been provided into the epidemiology (Incidence and Prevalence) section of the Autosomal dominant polycystic kidney disease (ADPKD) and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China
Considering AKPKD is an orphan drug designation with premium pricing benefits, the number of patients to be treated will be substantial and finally, no curative treatment being approved to date companies like Reata Pharmaceuticals, Kadmon Corporation, Novartis, Palladio Biosciences, Genzyme, Pfizer are in the race to build their asset in this market.
Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published report across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial result throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.
Methylmalonic Acidemia (MMA) – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Von Willebrand Disease (VWD) – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Fragile X syndrome – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Hunter syndrome (Mucopolysaccharidosis Type II) – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Batten disease – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report– 2019 To 2030
Autism Spectrum Disorders (ASD) – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report– 2019 To 2030
Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India Contact no.: +91(124) 404-1731 Sales office 183-Asylum Street Hartford, CT-06103, USA USA +1 (267) 244-6955, Email firstname.lastname@example.org email@example.com
Menafn, Reportedtimes, PR-Wirein, iCN Internal Distribution, Research Newswire, English